🚀 VC round data is live in beta, check it out!
Zhejiang Wolwo Bio-Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zhejiang Wolwo Bio-Pharma and similar public comparables like Jafron Biomedical, Agios Pharmaceuticals, Zymeworks, Mesoblast and more.
Zhejiang Wolwo Bio-Pharma Overview
About Zhejiang Wolwo Bio-Pharma
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is a Chinese bio-pharmaceutical company. It is engaged in the research development, production and sales of allergic diseases diagnosis and treatment products. The product portfolio of the company covers dust mites drops, dust mites skin prick diagnosis kit, silk, and others.
Founded
2002
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$2B
Zhejiang Wolwo Bio-Pharma Financials
Zhejiang Wolwo Bio-Pharma reported last fiscal year revenue of $136M and EBITDA of $61M.
In the same fiscal year, Zhejiang Wolwo Bio-Pharma generated $129M in gross profit, $61M in EBITDA, and $47M in net income.
Revenue (LTM)
Zhejiang Wolwo Bio-Pharma P&L
In the most recent fiscal year, Zhejiang Wolwo Bio-Pharma reported revenue of $136M and EBITDA of $61M.
Zhejiang Wolwo Bio-Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $136M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $129M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 95% | XXX | XXX | XXX |
| EBITDA | — | XXX | $61M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 45% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 36% | XXX | XXX | XXX |
| Net Profit | — | XXX | $47M | XXX | XXX | XXX |
| Net Margin | — | XXX | 34% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Zhejiang Wolwo Bio-Pharma Stock Performance
Zhejiang Wolwo Bio-Pharma has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Zhejiang Wolwo Bio-Pharma's stock price is $3.92.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -1.3% | XXX | XXX | XXX | $0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZhejiang Wolwo Bio-Pharma Valuation Multiples
Zhejiang Wolwo Bio-Pharma trades at 13.7x EV/Revenue multiple, and 30.4x EV/EBITDA.
EV / Revenue (LTM)
Zhejiang Wolwo Bio-Pharma Financial Valuation Multiples
As of April 18, 2026, Zhejiang Wolwo Bio-Pharma has market cap of $2B and EV of $2B.
Equity research analysts estimate Zhejiang Wolwo Bio-Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zhejiang Wolwo Bio-Pharma has a P/E ratio of 44.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 13.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 30.4x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 38.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 14.4x | XXX | XXX | XXX |
| P/E | — | XXX | 44.1x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 87.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zhejiang Wolwo Bio-Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Zhejiang Wolwo Bio-Pharma Margins & Growth Rates
Zhejiang Wolwo Bio-Pharma's revenue in the last fiscal year grew by 9%.
Zhejiang Wolwo Bio-Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 45% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 8% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 36% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Zhejiang Wolwo Bio-Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zhejiang Wolwo Bio-Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Jafron Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| Agios Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Zymeworks | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| Amylyx Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhejiang Wolwo Bio-Pharma M&A Activity
Zhejiang Wolwo Bio-Pharma acquired XXX companies to date.
Last acquisition by Zhejiang Wolwo Bio-Pharma was on XXXXXXXX, XXXXX. Zhejiang Wolwo Bio-Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Zhejiang Wolwo Bio-Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialZhejiang Wolwo Bio-Pharma Investment Activity
Zhejiang Wolwo Bio-Pharma invested in XXX companies to date.
Zhejiang Wolwo Bio-Pharma made its latest investment on XXXXXXXX, XXXXX. Zhejiang Wolwo Bio-Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Zhejiang Wolwo Bio-Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zhejiang Wolwo Bio-Pharma
| When was Zhejiang Wolwo Bio-Pharma founded? | Zhejiang Wolwo Bio-Pharma was founded in 2002. |
| Where is Zhejiang Wolwo Bio-Pharma headquartered? | Zhejiang Wolwo Bio-Pharma is headquartered in China. |
| Is Zhejiang Wolwo Bio-Pharma publicly listed? | Yes, Zhejiang Wolwo Bio-Pharma is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Zhejiang Wolwo Bio-Pharma? | Zhejiang Wolwo Bio-Pharma trades under 300357 ticker. |
| When did Zhejiang Wolwo Bio-Pharma go public? | Zhejiang Wolwo Bio-Pharma went public in 2014. |
| Who are competitors of Zhejiang Wolwo Bio-Pharma? | Zhejiang Wolwo Bio-Pharma main competitors are Jafron Biomedical, Agios Pharmaceuticals, Zymeworks, Mesoblast. |
| What is the current market cap of Zhejiang Wolwo Bio-Pharma? | Zhejiang Wolwo Bio-Pharma's current market cap is $2B. |
| What is the current revenue of Zhejiang Wolwo Bio-Pharma? | Zhejiang Wolwo Bio-Pharma's last fiscal year revenue is $136M. |
| What is the current EV/Revenue multiple of Zhejiang Wolwo Bio-Pharma? | Current revenue multiple of Zhejiang Wolwo Bio-Pharma is 13.7x. |
| Is Zhejiang Wolwo Bio-Pharma profitable? | No, Zhejiang Wolwo Bio-Pharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.